Drug Trial Radar · NCT06962800
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Jan 28, 2030
Study completion Jan 17, 2031
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- May 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease. The main question that researchers want to answer is: * How many participants achieve a complete response after 104 weeks of treatment? * A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable. Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * How many participants develop antibodies against felzartamab in the blood? * How many participants achieve a complete response after 76 weeks of treatment * How many participants have medical problems during the study * How felzartamab is processed by the body * How felzartamab affects participants' tiredness and overall physical health The study will be done as follows: * Participants will be screened to check if they can join the study. This may take up to 42 days. * Participants will be randomized to receive either felzartamab as intravenous (IV) infusions or tacrolimus, taken orally as tablets. * If participants have worsening kidney function or worsening proteinuria, or if their PMN relapses, or if they show no signs of improvement in their PMN, they will have a chance to receive rescue treatment. * If a participant stops treatment early, there will be follow-up visits every 12 weeks until they reach Week 104. * In total, participants will have up to 23 study visits. Participants who do not need rescue treatment will stay in the study for up to 104 weeks. Participants who need rescue treatment will stay in the study for up to 156 weeks.
Conditions
- Primary Membranous Nephropathy
Interventions
FelzartamabDrug
Administered intravenously
TacrolimusDrug
Administered orally
Standard of Care ISTDrug
Administered intravenously and orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who Achieve Complete Remission (CR) at Week 104Time frame: Week 104
Locations
117 sites in 11 countries. Site status is shown where the registry gives one.
Apogee Clinical Research, LLC
Huntsville, Alabama · Recruiting
The Nephrology Group, Inc. - Fresno
Fresno, California · Recruiting
Academic Medical Research Institute
Los Angeles, California · Recruiting
UCLA Health Connie Frank Kidney Transplant Center and General Nephrology
Los Angeles, California · Recruiting
UCSF Medical Center
San Francisco, California · Recruiting
Stanford University
Stanford, California · Recruiting
Henry Ford Hospital- A-Basement Research Pharmacy
Detroit, Michigan · Recruiting
Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS
Pontiac, Michigan · Completed
James J Peters Veterans Administration Medical Center - NAVREF - PPDS
The Bronx, New York · Recruiting
ECU Physicians Nephrology and Hypertension
Greenville, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Knoxville Kidney Center, PLLC
Knoxville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Nephrotex Research Group
Dallas, Texas · Recruiting
University of Texas Medical Branch
League City, Texas · Recruiting
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin · Recruiting
Organización Médica de Investigación
Buenos Aires, Argentina · Recruiting
CINME S.A. - Centro de Investigaciones Metabólicas
Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Recruiting
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Argentina · Recruiting
Clínica Privada Vélez Sarsfield
Córdoba, Argentina · Recruiting
Concord Hospital
Concord, New South Wales, Australia · Recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Townsville Hospital
Douglas, Queensland, Australia · Recruiting
Royal Brisbane and Women s Hospital
Herston, Queensland, Australia · Recruiting
Gold Coast University Hospital
Southport, Queensland, Australia · Recruiting
Griffith University Clinical Trial Unit
Southport, Queensland, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Sunshine Hospital - Australia
St Albans, Victoria, Australia · Recruiting
Hospital Alemao Oswaldo Cruz (HAOC)
São Paulo, Brazil · Recruiting
Centro de Pesquisa Clínica de Nefrologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil · Recruiting
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
Ribeirão Preto, São Paulo, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
São José do Rio Preto, São Paulo, Brazil · Recruiting
Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada · Recruiting
London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada · Recruiting
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.